Divergence phenomenon of EGFR-TKI in the treatment of non small cell lung cancer

被引：0

作者：

Zhang, Xia ^{[1
]}

Liu, Chang ^{[1
]}

Li, Juan ^{[1
]}

Song, Fei-xiang ^{[1
]}

Ruan, Xin-jian ^{[1
]}

Jia, Zhi-ling ^{[1
]}

机构：

[1] Beijing Mil Area Gen Hosp, Dept Oncol, Beijing 100007, Peoples R China

来源：

SCIENTIFIC RESEARCH AND ESSAYS | 2010年 / 5卷 / 24期

关键词：

Non small-cell lung cancer; tyrosine kinase inhibitor; divergence phenomenon; gefitinib; targeted therapy; BRAIN METASTASES; BONE METASTASIS; GEFITINIB; MUTATIONS;

D O I：

暂无

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The present study investigated the characteristic of the divergent efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) Gefitinib in treating non small-cell lung cancer (NSCLC) and discussed the strategy. The divergent efficacy of gefitinib was analyzed in 4 NSCLC patients at Beijing Military Area General Hospital between 2006 and 2010. The divergence phenomenon may occur in gefitinib-treated NSCLC patients with bone or brain metastases. One patient with primary lung disease under control still benefited from continuing Gefitinib therapy after disease progression in metastatic bone lesion. The divergence of efficacy is a common phenomenon in Gefitinib-treated NSCLC patients. The evaluation criteria available for anti-cancer therapies may not be completely suitable for molecular targeted therapies. The underlying mechanism deserves further research to formulate the efficacy evaluation criteria and therapeutic strategy for the molecular targeted therapy.

引用

页码：3967 / 3971

页数：5

共 15 条

[1] Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice [J].

Angelucci, A ;

Gravina, GL ;

Rucci, N ;

Millimaggi, D ;

Festuccia, C ;

Muzi, P ;

Teti, A ;

Vicentini, C ;

Bologna, M .

[2] Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial [J].

Ceresoli, GL ;

Cappuzzo, F ;

Gregorc, V ;

Bartolini, S ;

Crinó, L ;

Villa, E .

ANNALS OF ONCOLOGY, 2004, 15 (07) :1042-1047

[3] Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity [J].

Chiu, CH ;

Tsai, CM ;

Chen, YM ;

Chiang, SC ;

Liou, JL ;

Perng, RP .

LUNG CANCER, 2005, 47 (01) :129-138

[4] Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer [J].

Hotta, K ;

Kiura, K ;

Ueoka, H ;

Tabata, M ;

Fujiwara, K ;

Kozuki, T ;

Okada, T ;

Hisamoto, A ;

Tanimoto, M .

LUNG CANCER, 2004, 46 (02) :255-261

[5] Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer [J].

Inukai, Michio ;

Toyooka, Shinichi ;

Ito, Sachio ;

Asano, Hiroaki ;

Ichihara, Shuji ;

Soh, Junichi ;

Suehisa, Hiroshi ;

Ouchida, Mamoru ;

Aoe, Keisuke ;

Aoe, Motoi ;

Kiura, Katsuyuki ;

Shimizu, Nobuyoshi ;

Date, Hiroshi .

CANCER RESEARCH, 2006, 66 (16) :7854-7858

[6] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[7]

Namba Yoshinobu, 2004, Clin Lung Cancer, V6, P123, DOI 10.3816/CLC.2004.n.026

[8] Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis [J].

Normanno, N ;

De Luca, A ;

Aldinucci, D ;

Maiello, MR ;

Mancino, M ;

D'Antonio, A ;

De Filippi, R ;

Pinto, A .

[9] High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib [J].

Omuro, AMP ;

Kris, MG ;

Miller, VA ;

Franceschi, E ;

Shah, N ;

Milton, DT ;

Abrey, LE .

CANCER, 2005, 103 (11) :2344-2348

[10] EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy [J].

Paez, JG ;

Jänne, PA ;

Lee, JC ;

Tracy, S ;

Greulich, H ;

Gabriel, S ;

Herman, P ;

Kaye, FJ ;

Lindeman, N ;

Boggon, TJ ;

Naoki, K ;

Sasaki, H ;

Fujii, Y ;

Eck, MJ ;

Sellers, WR ;

Johnson, BE ;

Meyerson, M .

SCIENCE, 2004, 304 (5676) :1497-1500

← 1 2 →